Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2 Million Upfront Payment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2 Million Upfront Payment

Navidea Biopharma (NAVB) Reports In-Line Q4 EPS

March 5, 2015 7:31 AM EST

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

... More

Navidea Biopharma (NAVB), SpePharm AG Emter Distribution Agreement for Lymphoseek in EU

March 5, 2015 7:16 AM EST

Navidea Biopharma (AMEX: NAVB) and SpePharm AG (an affiliate of Norgine BV), a European specialist pharmaceutical company with an extensive pan-European presence, entered into an exclusive sublicense agreement for the commercialization and distribution of Lymphoseek® 250 microgram kit for radiopharmaceutical preparation (tilmanocept) in the European Union. Under the terms of the agreement, Navidea will receive an upfront payment of $2 million and is eligible to receive additional milestone payments up to $5 million, as well as royalties on European net sales.

Lymphoseek is a receptor-targeted, radiopharmaceutical imaging agent approved by the U.S. Food... More